Navigation Links
BioView Reports Interim Results of Early Detection Lung Cancer Diagnostic Test
Date:9/24/2008

REHOVOT, Israel, September 24 /PRNewswire-FirstCall/ -- BioView Ltd, (TASE: BIOV) from Rehovot, Israel, reported today results of its internal clinical trial of the non-invasive diagnostic test under development for early detection of lung cancer.

In the trial a total of 76 sputum samples were collected from four groups of patients:

1. Healthy individuals that never smoked

2. Heavy smokers with no signs of lung cancer

3. Early stage lung cancer patients (Stage 1)

4. Advanced stage lung cancer patients

The sputum samples were blindly scanned and analyzed morphologically and genetically, with fluorescent probes exclusively licensed to BioView, on BioView's automated Duet scanning station by Company personnel. The results of the test were classified as "Normal", i.e. no cancer detected and "Abnormal", i.e. Cancer detected. These results were then compared to the actual data received from the hospital of the patients' condition.

The samples included 32 cases of lung cancer patients (about half of them early stage patients) and 44 samples taken from people with no clinical evidence of lung cancer. Thirty one of the thirty two (96.9%) sick patients were correctly diagnosed as "Abnormal" and thirty six of forty four (about 82%) healthy people were correctly diagnosed as "Normal".

Project leader, Dr. Michal Daniely says:"We have gained great confidence in this test as we see a direct relationship between our results and the clinical status of the patients".

Dr. Opher Shapira, BioView's CEO commented: "We are extremely pleased with the results; the specificity and sensitivity in this test are better than other non-invasive tests presently available for early lung cancer detection. We are accelerating our development efforts to improve these results as well as to increase our sample size and to include other laboratories in the clinical trials."

BioView lung cancer test in based on morphological and genetic analysis of sputum samples and it is running on BioView DUETTM automated scanning platform.

About BioView Ltd.

Established in 2000, and led by an expert team of biologists, software engineers and physicists, BioView develops, manufactures and supplies cell imaging equipment, biological kits and software to medical institutes and universities. BioView is a publicly traded company on the Israeli Stock exchange, and currently has strategic collaborations underway with international scientific leaders and institutions. For more information about the BioView technology, and press related issues, please contact info@bioview.co.il or visit our website at http://www.bioview.co.il.

Dr. Opher Shapira

President and CEO

Tel: +972-8-936-6868

Fax: +972-8-936-6869

e-mail: opher@bioview.co.il


'/>"/>
SOURCE BioView Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Bioheart Reports Promising Results From Preclinical Study of Adipose-Derived Acute Cell Therapy
2. MannKind Reports Positive Data from a Phase 3 Clinical Study of Technosphere Insulin in Type 1 Diabetes
3. Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate
4. Nutrition 21 Reports That National Toxicology Program Studies Support the Safety of Chromium Picolinate
5. Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma
6. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
7. Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin
8. Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
9. Cardium Reports on Second Quarter 2008 Highlights and Financial Results
10. Nature Publication Reports on Key Role of Bile Acids in Glucose Metabolism and Insulin Signaling
11. Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... PUNE, India , June 24, 2016 ... "Pen Needles Market by Type (Standard Pen Needles, Safety ... 12mm), Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase ... published by MarketsandMarkets, This report studies the market for ... is expected to reach USD 2.81 Billion by 2021 ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... - Forecast to 2022" report to their offering. ... to date financial data derived from varied research sources to ... potential impact on the market during the next five years, ... of sub markets, regional and country level analysis. The report ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating ... many ways they remain in the eye of the beholder, according to experts who ... of The American Journal of Managed Care. For the full issue, click here ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... that was developed to enhance the health of felines. The formula is all-natural and ... main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from ... at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center ... care topics including advance care planning, healthcare costs and patient and family engagement. ...
(Date:6/25/2016)... ... 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can ... CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn ... X . Simply select a ProHand generator and drag it above media or text ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
Breaking Medicine News(10 mins):